Fresenius Medical Care
Fresenius Medical Care, a leading global provider of products and services for individuals with renal diseases, is headquartered in the United States. Founded in 1996, the company has established a strong presence in North America, Europe, and Asia, focusing on dialysis services and the manufacture of dialysis equipment. With a commitment to innovation, Fresenius Medical Care offers a comprehensive range of products, including dialysis machines and consumables, which are distinguished by their advanced technology and patient-centric design. The company is recognised for its significant market position, serving millions of patients worldwide and achieving notable milestones in improving patient outcomes. As a key player in the healthcare industry, Fresenius Medical Care continues to lead in the development of integrated care solutions, enhancing the quality of life for those affected by chronic kidney disease.
DitchCarbon Score
How does Fresenius Medical Care's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Medical Care's score of 56 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Medical Care's reported carbon emissions
In 2024, Fresenius Medical Care reported total carbon emissions of approximately 3,680,827,000 kg CO2e. This figure includes 360,803,000 kg CO2e from Scope 1 emissions (direct emissions), 326,636,000 kg CO2e from Scope 2 emissions (indirect emissions from energy), and a significant 2,993,388,000 kg CO2e from Scope 3 emissions, which encompass a wide range of activities including purchased goods and services (1,385,959,000 kg CO2e) and the use of sold products (847,284,000 kg CO2e). Fresenius Medical Care has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 50% by 2030, compared to 2020 levels. This target reflects a strong commitment to sustainability and aligns with their broader net-zero goals, which have been officially committed to by 2050 across all scopes of emissions. The company has demonstrated progress in its emissions reporting, with comprehensive disclosures across all relevant scopes. Their initiatives are supported by the Science Based Targets initiative (SBTi), which confirms their commitment to long-term climate goals. The emissions data and reduction targets are sourced directly from Fresenius Medical Care AG, ensuring accuracy and accountability in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Medical Care is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
